3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Transitional Cell
16
Urinary Bladder Neoplasms
15
Carcinoma, Merkel Cell
10
Neoplasm Metastasis
8
Carcinoma, Renal Cell
8
Breast Neoplasms
8
Neoplasms
6
Triple Negative Breast Neoplasms
5
Melanoma
5
Ureteral Neoplasms
4
Stomach Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Ovarian Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Urethral Neoplasms
3
Skin Neoplasms
3
Prostatic Neoplasms
3
Colorectal Neoplasms
3
Uterine Cervical Neoplasms
2
Small Cell Lung Carcinoma
2
Sarcoma
2
Neuroendocrine Tumors
2
Head and Neck Neoplasms
2
Endometrial Neoplasms
2
Carcinoma, Squamous Cell
2
Carcinoma, Hepatocellular
2
Uveal Melanoma
1
Urothelial Cancer
1
Turcot syndrome
1
Thymoma
1
Interventions
Sunitinib
2
spartalizumab
1
pembrolizumab
1
palbociclib
1
enzalutamide
1
bicalutamide
1
avelumab
1
aldesleukin
1
Specimen Handling
1
Receptors, Androgen
1
Leuprolide
1
Interleukin-2
1
Health Information Exchange
1
Goserelin
1
Flutamide
1
Blood Specimen Collection
1
Axitinib
1
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kidney Diseases
×
avelumab
×
1 year
×
Clear all
NCT02684006
2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3
Completed
886 enrolled
37 charts
1 FDA